Highly successful therapeutic vaccinations combining dendritic cells and tumor cells secreting granulocyte macrophage colony-stimulating factor

Cancer Research

Volumn 64, Issue 22, 2004, Pages 8435-8442

  Driessens, Gregory ^a,c   Hamdane, Malika ^a   Cool, Vincent ^a   Velu, Thierry ^a,b   Bruyns, Catherine ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c Fonds Pour Form Rech Dans l'I ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LYMPHOCYTE ANTIGEN; MITOMYCIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFICACY; GENE TRANSFER; GENETIC TRANSDUCTION; GLIOSARCOMA; IMMUNOSTIMULATION; MALE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR CELL; TUMOR REGRESSION; VACCINATION;

ANIMALS; APOPTOSIS; CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; GLIOSARCOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; MALE; RATS; RATS, INBRED F344;

EID: 8544280001     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0774     Document Type: Article

References (44)

1. Nanni P, Forni G, Lollini PL. Cytokine gene therapy: hopes and pitfalls. Ann Oncol 1999;10:261-6.
2. Tepper RI, Mule JJ. Experimental and clinical-studies of cytokine gene-modified tumor-cells. Hum Gene Ther 1994;5:153-64.
3. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001;106:271-4.
4. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 2002;188:147-54.
5. Huang AY, Golumbek P, Ahmadzadeh M, et al. Role of bone-marrow-derived cells in presenting MHC class I-restricted tumor-antigens. Science (Wash DC) 1994;264:961-5.
6. Mach N, Gillessen S, Wilson SB, et al. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 2000;60:3239-46.
7. Herrlinger U, Kramm CM, Johnston KM, et al. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther 1997;4:345-52.
8. Wallenfriedman MA, Conrad JA, DelaBarre L, et al. Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression. J Neurosurg 1999;90:1064-71.
9. Lefranc F, Cool V, Velu T, Brotchi J, De Witte O. Granulocyte macrophage-colony stimulating factor gene transfer to induce a protective anti-tumoral immune response against the 9L rat gliosarcoma model. Int J Oncol 2002;20:1077-85.
10. Lechanteur C, Moutschen M, Princen F, et al. Antitumoral vaccination with granulocyte-macrophage colony-stimulating factor or interleukin-12-expressing DHD/K12 colon adenocarcinoma cells. Cancer Gene Ther 2000;7:676-82.
11. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
12. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003;15:138-47.
13. Soling A, Rainov NG. Dendritic cell therapy of primary brain tumors. Mol Med 2001;7:659-67.
14. Zhou Y, Bosch ML, Salgaller ML. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother 2002;25:289-303.
15. Bhardwaj N. Processing and presentation of antigens by dendritic cells: implications for vaccines. Trends Mol Med 2001;7:388-94.
16. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I- restricted CTLs. Nature (Lond) 1998;392:86-9.
17. Harshyne LA, Watkins SC, Gambotto A, Barratt-Boyes SM. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J Immunol 2001;166:3717-23.
18. Nouri-Shirazi M, Banchereau J, Bell D, et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000;165:3797-803.
19. Chen Z, Moyana T, Saxena A, et al. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer 2001;93:539-48.
20. Herr W, Ranieri E, Olson W, et al. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood 2000;96:1857-64.
21. Kotera Y, Shimizu K, Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 2001;61:8105-9.
22. Witham TF, Erff ML, Okada H, Chambers WH, Pollack IF. 7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model. Neurosurgery (Baltim) 2002;50:1327-34.
23. Cerundolo V. Tumour immunology: T cells work together to fight cancer. Curr Biol 1999;9:R695-7.
24. Janssen EM, Lemmens EE, Wolfe T, et al. CD4(+) T cells are required for secondary expansion and memory in CD8(+) T lymphocytes. Nature (Lond) 2003;421:852-6.
25. Chen-Woan M, Delaney CP, Fournier V, et al. A new protocol for the propagation of dendritic cells from rat bone marrow using recombinant GM-CSF, and their quantification using the mAb OX-62. J Immunol Methods 1995;178:157-71.
26. Driessens G, Harsan L, Robaye B, et al. Micronuclei to detect in vivo chemotherapy damage in a p53 mutated solid tumour. Br J Cancer 2003;89:727-9.
27. Sauter B, Albert ML, Francisco L, et al. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000;191:423-34.
28. Siesjo P, Visse E, Sjogren HO. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment. J Immunother Emphasis Tumor Immunol 1996;19:334-45.
29. Nemunaitis J, Sterman D, Jablons D, et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst (Bethesda) 2004;96:326-31.
30. Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998;95:13141-6.
31. Pan PY, Li Y, Li Q, et al. In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery. Cancer Immunol Immunother 2004;53:17-25.
32. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
33. Kinoshita Y, Kono T, Yasumoto R, et al. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells. J Immunother 2001;24:205-11.
34. Henry F, Boisteau O, Bretaudeau L, et al. Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res 1999;59:3329-32.
35. Shi FS, Weber S, Gan J, Rakhmilevich AL, Mahvi DM. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF. Cancer Gene Ther 1999;6:81-8.
36. Kurane S, Area MT, Aruga A, et al. Cytokines as an adjuvant to tumor vaccines: efficacy of local methods of delivery. Ann Surg Oncol 1997;4:579-85.
37. Daro E, Pulendran B, Brasel K, et al. Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but not CD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J Immunol 2000;165:49-58.
38. Nishisaka N, Maini A, Kinoshita Y, et al. Immunotherapy for lung metastases of murine renal cell carcinoma: synergy between radiation and cytokine-producing tumor vaccines. J Immunother 1999;22:308-14.
39. Strome SE, Voss S, Wilcox R, et al. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res 2002;62:1884-9.
40. Scheffer SR, Nave H, Korangy F, et al. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer 2003;103:205-11.
41. Nikitina EY, Gabrilovich DI. Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int J Cancer 2001;94:825-33.
42. Paczesny S, Ueno H, Fay J, Banchereau J, Palucka AK. Dendritic cells as vectors for immunotherapy of cancer. Semin Cancer Biol 2003;13:439-47.
43. Bonnotte B, Favre N, Moutet M, et al. Role of tumor cell apoptosis in tumor antigen migration to the draining lymph nodes. J Immunol 2000;164:1995-2000.
44. Kleindienst P, Brocker T. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo. J Immunol 2003;170:2817-23.